This is a routine pipeline update with no financial data or material changes. The 1-log cccDNA reduction in HBV is a positive mechanistic readout but was previously reported. The DMD site activation is incremental. Both programs target year-end 2026 for next updates — no near-term catalyst. Monitor for actual data releases at year-end.
Price Chart
Executive Summary
Precision BioSciences updated its corporate deck, highlighting PBGENE-HBV clinical data showing a 1-log (10-fold) reduction in cccDNA-derived transcripts from the ELIMINATE-B study for chronic hepatitis B, and announced activation of a second clinical site for the FUNCTION-DMD trial evaluating PBGENE-DMD for Duchenne muscular dystrophy. Both programs target year-end 2026 for next updates. The filing is a routine pipeline update with no financial data or material changes.
Key Facts
- PBGENE-HBV liver biopsy data showed 1-log (10-fold) reduction in cccDNA-derived transcripts in the ELIMINATE-B study for chronic hepatitis B
- Next program update for PBGENE-HBV targeted for year-end 2026
- Second clinical site activated at Washington University School of Medicine for the FUNCTION-DMD trial evaluating PBGENE-DMD for Duchenne muscular dystrophy
- Initial safety data for PBGENE-DMD targeted for year-end 2026
- No financial data, guidance, or material agreements disclosed in this filing
Financial Impact
No financial data disclosed in this filing
Risk Factors
- No financial data or guidance provided — pipeline updates are qualitative and forward-looking
- Both programs are early-stage with no approved products; clinical failure risk remains high
- No disclosure of cash runway or financing plans — potential dilution risk for a pre-revenue biotech
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-046340 |
| Document: 0001628280-26-046340-index-headers.html | 0001628280-26-046340 |
| Document: 0001628280-26-046340-index.html | 0001628280-26-046340 |
| Document: 0001628280-26-046340.txt | 0001628280-26-046340 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $7.19 $6.36 | ▼ −11.54% | ▼ −10.82% | $6.41 (−10.85%) |
Aug 24, 2026 9w ago | 8-K | $8.45 $8.55 | ▲ +1.18% | ▲ +0.86% | $6.41 (−24.14%) |
Aug 6, 2026 11w ago | 8-K | $7.42 $7.49 | ▲ +0.94% | ▲ +0.33% | $6.41 (−13.61%) |
Jul 27, 2026 13w ago | 8-K | $7.25 $7.17 | ▼ −1.10% | ▼ −1.34% | $6.41 (−11.59%) |
Jul 1, 2026 16w ago | 8-K | $7.88 $8.18 | ▲ +3.81% | ▲ +3.94% | $6.41 (−18.65%) |
Jun 16, 2026 18w ago | 8-K | $6.50 $6.81 | ▲ +4.77% | ▲ +3.99% | $6.41 (−1.38%) |
May 27, 2026 21w ago | 8-K | $7.59 $6.92 | ▼ −8.83% | ▼ −9.38% | $6.41 (−15.55%) |
May 26, 2026 21w ago | 8-K | $7.59 $6.92 | ▼ −8.83% | ▼ −9.38% | $6.41 (−15.55%) |
May 5, 2026 24w ago | 8-K | $7.45 $7.52 | ▲ +0.94% | ▼ −0.45% | $6.41 (−13.96%) |
Apr 8, 2026 28w ago | DEFA14A | $5.99 $6.61 | ▲ +10.35% | ▲ +9.78% | $6.41 (+7.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers